Cai Maoping, Song Xian-Lu, Li Xin-An, Chen Mingkun, Guo Jiading, Yang Dong-Hua, Chen Zhanghui, Zhao Shan-Chao
Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, Guangdong, PR China; The Third Clinical College, Southern Medical University, Guangzhou 510630, Guangdong, PR China; Zhanjiang Institute of Clinical Medicine, Central People's Hospital of Zhanjiang, Zhanjiang 524045, Guangdong, PR China.
Department of Radiotherapy, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, Guangdong, PR China.
Drug Resist Updat. 2023 May;68:100962. doi: 10.1016/j.drup.2023.100962. Epub 2023 Apr 14.
Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of cancer-related death among men in the world. In addition, it is very difficult for clinical treatment because of the natural or acquired drug resistance of CRPC. Mechanisms of drug resistance are extremely complicated and how to overcome it remains an urgent clinical problem to be solved. Thus, a comprehensive and thorough understanding for mechanisms of drug resistance in mCRPC is indispensable to develop novel and better therapeutic strategies. In this review, we aim to review new insight of the treatment of mCRPC and elucidate mechanisms governing resistance to new drugs: taxanes, androgen receptor signaling inhibitors (ARSIs) and poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi). Most importantly, in order to improve efficacy of these drugs, strategies of overcoming drug resistance are also discussed based on their mechanisms respectively.
去势抵抗性前列腺癌（CRPC），尤其是转移性去势抵抗性前列腺癌（mCRPC），是全球男性中最常见的恶性肿瘤之一，也是癌症相关死亡的主要原因。此外，由于CRPC的天然或获得性耐药性，临床治疗非常困难。耐药机制极其复杂，如何克服耐药性仍然是一个亟待解决的临床问题。因此，全面深入地了解mCRPC的耐药机制对于开发新的、更好的治疗策略是必不可少的。在这篇综述中，我们旨在回顾mCRPC治疗的新见解，并阐明对新药（紫杉烷类、雄激素受体信号抑制剂（ARSIs）和聚（ADP-核糖）聚合酶（PARP）抑制剂（PARPi））产生耐药性的机制。最重要的是，为了提高这些药物的疗效，还分别根据其机制讨论了克服耐药性的策略。
